Missouriwatcher
Editor, Senior Moderator
This is an official
CDC HEALTH UPDATE
Distributed via Health Alert Network
Friday, January 14, 2011, 16:11 EDT (4:11 PM EDT)
Summary
As influenza activity increases in the United States, clinicians are urged to consult CDC guidance on the use of influenza antiviral agents and rapid influenza diagnostic tests this season. Updated recommendations on the use of antiviral medications will be published in an upcoming Morbidity and Mortality Weekly Report (MMWR), but an interim version of the recommendations is currently available on CDC’s website at http://www.cdc.gov/flu/professionals/antivirals/index.htm. The updated guidance for health care professionals on the use of rapid influenza diagnostic tests is available at http://www.cdc.gov/flu/professionals/diagnosis/clinician_guidance_ridt.htm. For the most recent summary of influenza activity in the United States, consult the CDC influenza surveillance report FluView at http://www.cdc.gov/flu/weekly/fluactivitysurv.htm.
Recommendations
Antiviral Agents Guidance:
The recommendations on the use of influenza antiviral agents contain information on treatment and chemoprophylaxis of influenza virus infection, and also provide a summary of the effectiveness and safety of antiviral medications. Highlights include recommendations for the following:
1. early empiric antiviral treatment of suspected or confirmed influenza among people with severe, complicated, or progressive illness or those hospitalized for influenza;
2. early empiric antiviral treatment of suspected or confirmed influenza among people at higher risk for influenza complications;
3. use of either oseltamivir or zanamivir for influenza A and B treatment or chemoprophylaxis, and recommendations not to use rimantadine or amantadine as influenza antiviral medications due to high levels of resistance to these medications among circulating influenza A viruses;
4. use of antiviral medications among children younger than 1 year of age;
5. use of local data on influenza virus circulation and influenza testing of respiratory specimens from patients with suspected influenza, when available, to help inform clinicians about influenza circulation; and
6. consideration of antiviral treatment for any previously healthy, non high-risk symptomatic outpatient with confirmed or suspected influenza, based upon clinical judgment, if treatment can be initiated within 48 hours of illness onset.
Antiviral Agents Guidance:
The recommendations on the use of influenza antiviral agents contain information on treatment and chemoprophylaxis of influenza virus infection, and also provide a summary of the effectiveness and safety of antiviral medications. Highlights include recommendations for the following:
1. use of rapid influenza diagnostic tests when a positive result will change the clinical management of patients or change outbreak control strategies in a population, especially if the setting includes hospitalized patients or persons at high risk for influenza-associated complications;
2. avoiding the use of negative rapid test results to guide decisions regarding treating patients with influenza antiviral medications due to the suboptimal sensitivity of rapid tests;
3. evaluation of rapid diagnostic test results in the context of other available clinical and epidemiological information; and
4. consideration of further influenza laboratory testing in the following circumstances:
* when a patient tests negative by rapid test during periods of high influenza activity;
* when a patients tests positive by rapid test during periods of low influenza activity; or
* when a patient has had recent close exposure to pigs, poultry, or other animals and novel influenza A virus infection is possible...
http://www2a.cdc.gov/HAN/ArchiveSys/ViewMsgV.asp?AlertNum=00318
CDC HEALTH UPDATE
Distributed via Health Alert Network
Friday, January 14, 2011, 16:11 EDT (4:11 PM EDT)
Summary
As influenza activity increases in the United States, clinicians are urged to consult CDC guidance on the use of influenza antiviral agents and rapid influenza diagnostic tests this season. Updated recommendations on the use of antiviral medications will be published in an upcoming Morbidity and Mortality Weekly Report (MMWR), but an interim version of the recommendations is currently available on CDC’s website at http://www.cdc.gov/flu/professionals/antivirals/index.htm. The updated guidance for health care professionals on the use of rapid influenza diagnostic tests is available at http://www.cdc.gov/flu/professionals/diagnosis/clinician_guidance_ridt.htm. For the most recent summary of influenza activity in the United States, consult the CDC influenza surveillance report FluView at http://www.cdc.gov/flu/weekly/fluactivitysurv.htm.
Recommendations
Antiviral Agents Guidance:
The recommendations on the use of influenza antiviral agents contain information on treatment and chemoprophylaxis of influenza virus infection, and also provide a summary of the effectiveness and safety of antiviral medications. Highlights include recommendations for the following:
1. early empiric antiviral treatment of suspected or confirmed influenza among people with severe, complicated, or progressive illness or those hospitalized for influenza;
2. early empiric antiviral treatment of suspected or confirmed influenza among people at higher risk for influenza complications;
3. use of either oseltamivir or zanamivir for influenza A and B treatment or chemoprophylaxis, and recommendations not to use rimantadine or amantadine as influenza antiviral medications due to high levels of resistance to these medications among circulating influenza A viruses;
4. use of antiviral medications among children younger than 1 year of age;
5. use of local data on influenza virus circulation and influenza testing of respiratory specimens from patients with suspected influenza, when available, to help inform clinicians about influenza circulation; and
6. consideration of antiviral treatment for any previously healthy, non high-risk symptomatic outpatient with confirmed or suspected influenza, based upon clinical judgment, if treatment can be initiated within 48 hours of illness onset.
Antiviral Agents Guidance:
The recommendations on the use of influenza antiviral agents contain information on treatment and chemoprophylaxis of influenza virus infection, and also provide a summary of the effectiveness and safety of antiviral medications. Highlights include recommendations for the following:
1. use of rapid influenza diagnostic tests when a positive result will change the clinical management of patients or change outbreak control strategies in a population, especially if the setting includes hospitalized patients or persons at high risk for influenza-associated complications;
2. avoiding the use of negative rapid test results to guide decisions regarding treating patients with influenza antiviral medications due to the suboptimal sensitivity of rapid tests;
3. evaluation of rapid diagnostic test results in the context of other available clinical and epidemiological information; and
4. consideration of further influenza laboratory testing in the following circumstances:
* when a patient tests negative by rapid test during periods of high influenza activity;
* when a patients tests positive by rapid test during periods of low influenza activity; or
* when a patient has had recent close exposure to pigs, poultry, or other animals and novel influenza A virus infection is possible...
http://www2a.cdc.gov/HAN/ArchiveSys/ViewMsgV.asp?AlertNum=00318